Home » Newsletters » BioWorld Science

BioWorld Science

May 28, 2013

View Archived Issues

Ghrelin agonist tested in gastrointestinal symptoms related to Parkinson's disease

Global molecular signature for the prognosis of hepatocellular carcinoma identified

[11C]Cimbi-36 demonstrates utility for human brain imaging

Development of Sangamo BioSciences' ZFP beta-thalassemia treatment receives support

Novel pneumonia vaccine candidate induces systemic and mucosal immune response in vivo

In vivo results for a novel ApoC-II mimetic peptide reported

Oxford BioMedica develops a novel gene therapy for IOP

A novel PET tracer shows PDE10A specificity in rat and monkey striatum

Astellas Pharma will not seek European approval for tivozanib in RCC

Valeant Pharmaceuticals to acquire Bausch & Lomb

GSK and Tempero Pharmaceuticals jointly develop HDAC9 inhibitors

Recent Merck & Co. patents describe novel ROMK blockers

Novel nicotinic alpha4beta2 receptor ligands identified by Targacept

Italian researchers synthesize novel HSP 90 inhibitors

Vertex Pharmaceuticals discloses novel Na(v)1.7 blockers

Virobay begins phase I trial of oral pain treatment candidate VBY-036

PlantForm and PharmaPraxis collaborate on biosimilars/biobetters

Astellas' isavuconazole granted orphan drug status for invasive aspergillosis

Chembio awarded U.S. government contract to develop diagnostic tests

Eisai set to launch Inovelon tablets in Japan

4SC's Japanese partner Yakult Honsha begins phase I/II study of resminostat in liver cancer

Bayer's Xarelto approved in Europe for additional indication

AstraZeneca enters definitive agreement to acquire Omthera Pharmaceuticals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.